logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10285959 B1

PDFFull Text
Date of Patent:
May. 14, 2019

Filed:

Nov. 26, 2014

Combination therapies using hdac inhibitors

Applicant:

Topotarget Uk Limited, Abingdon, Oxfordshire, GB;

Inventors:

Henri Lichenstein, Branford, CT (US);

Mike Jeffers, Branford, CT (US);

Xiaozhang Qian, Branford, CT (US);

Maxwell Sehested, Copenhagen, DK;

Kamille Dumong Erichsen, Copenhagen, DK;

James Ritchie, Oxfordshire, GB;

Assignee:

TopoTarget UK Limited, , GB;

Attorney:

Lerner, David, Littenberg, Krumholz & Mentlik, LLP

Primary Examiner:

Anna Pagonakis

Int. Cl.
CPC ...
A61K 31/18 (2006.01); A61K 31/24 (2006.01); A61K 33/24 (2006.01); A61K 45/06 (2006.01); A61K 31/138 (2006.01); A61K 31/196 (2006.01); A61K 31/198 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/475 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/573 (2006.01); A61K 31/704 (2006.01); A61K 31/706 (2006.01); A61K 31/4745 (2006.01); A61K 31/7068 (2006.01); A61K 31/7076 (2006.01);
U.S. Cl.
CPC ...
A61K 31/18 (2013.01); A61K 31/138 (2013.01); A61K 31/196 (2013.01); A61K 31/198 (2013.01); A61K 31/24 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/573 (2013.01); A61K 31/704 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 31/7076 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01);
Abstract

The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount.

Find Patent Forward Citations

Loading…